Company intelligence / Profile preview

Macrocure Ltd.

Petach Tikva, Israelfinder.startupnationcentral.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Macrocure was a clinical-stage biotechnology company that developed a novel therapeutic platform for chronic and hard-to-heal wounds. Their product CureXcell was used for hard-to-heal wound treatment[3][5].

Therapeutic areas: Dermatology
Modalities: Advanced cell therapy products
Industry: Biotech

Drug pipeline

1 asset

CureXcell

Phase 3

Indications: Diabetic foot ulcers, Venous leg ulcers, Chronic wounds

Beyond the preview

Go deeper on Macrocure Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macrocure Ltd..

Explore the full profile